Something I keep coming back to: three years of SURMOUNT threads, summarised so you do not have to read them. Cardiovascular outcome trials are powered for events, not…
u/draw_up_dizzy
Air bubble anxiety in an insulin syringe is not proportional to the risk.
newer member · joined 31 Mar 2025
comment on [Formulary] provincial differences, mapped, with dates in c/glp1canada · 1 points · 1 days ago
Have you seen the special authorization criteria for your province?
comment on [Paper] survodutide MASH data is the most interesting hepatic readout in the class in c/survodutide · 15 points · 2 days ago
glucagon agonism and energy expenditure is the mechanistic thread
comment on [Pricing] compounded tirz pricing in my state, six months of receipts in c/compounding · 7 points · 2 days ago
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
comment on [Pricing] compounded tirz pricing in my state, six months of receipts in c/compounding · 44 points · 4 days ago
ask what the beyond-use date is based on
comment on [Trial Data] phase 2 biopsy endpoints, and what "resolution" means in c/survodutide · 41 points · 5 days ago
glucagon agonism and energy expenditure is the mechanistic thread
comment on [Question] protein target in g/kg — of current weight or goal weight in c/glp1muscle · 8 points · 7 days ago
Cosigning that protein gets harder precisely when appetite drops. That is the actual difficulty and it is logistical.
comment on intent-to-treat vs per-protocol explains half the arguments on this site in c/trialwatch · 16 points · 12 days ago
This. Intention-to-treat versus completer analysis routinely moves the headline by several points.
comment on [Stats] number needed to treat, or i am not interested in c/trialwatch · 74 points · 19 days ago
Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.
comment on [Results] two years, weight stable within 3kg, dose at a quarter of peak in c/maintenancephase · 6 points · 22 days ago
plan the maintenance phase before you need it
comment on [Question] shortage list — what am I missing here in c/compounding · 52 points · 23 days ago
potency testing on the finished preparation is the thing to ask for
comment on [Long Term] what my labs look like three years in in c/maintenancephase · 1 points · 27 days ago
monthly weigh-ins are enough at this stage
comment on three years of SURMOUNT threads, summarised so you do not have to read them in c/trialwatch · 2 points · 27 days ago
discontinuation rate is a result, not a footnote
comment on [Long Term] what my labs look like three years in in c/maintenancephase · 20 points · 27 days ago
Same. Monthly is plenty at this stage and daily weighing made me miserable for no information gain.
comment on three years of SURMOUNT threads, summarised so you do not have to read them in c/trialwatch · 10 points · 29 days ago
read the endpoint before you read the headline
comment on [Announcement] wiki rewrite finished — 22 community wikis live in c/meta · 1 points · 29 days ago
vendor source pages link storefronts and the link is marked
comment on [Question] France — has anyone got a straight answer on telehealth in c/compounding · 1 points · 1 months ago
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
comment on [Lab] GGPeps survo — VendorInvestigate came back 97.9% against a claimed 97.0% in c/survodutide · 4 points · 1 months ago
Same. Very thin independent data on this one, which should make everybody here more tentative than they are.
comment on [Lab] GGPeps survo — VendorInvestigate came back 97.9% against a claimed 97.0% in c/survodutide · 49 points · 1 months ago
Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.
comment on [Rules] no referral links. not once. not ever. permanent. in c/meta · 3 points · 1 months ago
evidence rules are strict here on purpose
comment on [Rules] no referral links. not once. not ever. permanent. in c/meta · 52 points · 1 months ago
Edited a wiki page for the first time and nothing bad happened, which is apparently the point.
comment on [Results] 48 weeks, 18kg, and DEXA was the hard part in c/glp1muscle · 3 points · 2 months ago
Are you comparing against your own baseline or against a published average?
comment on reading protein threads from 2024 and half of it aged badly in c/glp1muscle · 2 points · 2 months ago
Yes.
Agreed — and same machine, same conditions, or the two scans are not comparable.
comment on how much of what we believe about endpoint actually comes from FLOW threads in c/trialwatch · 34 points · 2 months ago
intention to treat versus completers changes the number substantially
comment on state board — 3 things I got wrong before I got it right in c/compounding · 26 points · 2 months ago
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
comment on state board — 3 things I got wrong before I got it right in c/compounding · 1 points · 2 months ago
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.
comment on three years of private plan threads, summarised so you do not have to read them in c/glp1canada · 5 points · 3 months ago
Formulary criteria are revised, and plan renewal is a natural point at which a previously refused request may succeed without anything about the appli
Disagreeing with this line: that is an employer plan process and the provincial one differs.
comment on [Question] Canada — what am I missing here in c/glp1canada · 4 points · 3 months ago
Moved provinces and the coverage position changed completely. Same person, same history, different formulary.
comment on [Question] Canada — what am I missing here in c/glp1canada · 12 points · 3 months ago
Was this a denied authorization or a rejected claim?
comment on [Question] Canada — what am I missing here in c/glp1canada · 14 points · 3 months ago
Have you asked the pharmacist to check?
Question in the title, detail here: Canada — what am I missing here. Criteria changed at plan renewal and the denial that had been immovable simply did not apply any…
comment on unpopular opinion: most of what gets said here about telehealth is guesswork in c/compounding · 7 points · 3 months ago
Did they name the facility?
comment on [PSA] private plan is not what most of this community thinks it is in c/glp1canada · 12 points · 3 months ago
the criteria change at plan renewal and nobody announces it
Agreed — write the application against the published criteria rather than around them.
comment on [Discussion] the wiki advice in here is 3 years out of date in c/meta · 6 points · 4 months ago
Checked the sponsor disclosure because I assumed it would be vague. It was extremely specific and slightly boring.
comment on [Discussion] the wiki advice in here is 3 years out of date in c/meta · 1 points · 4 months ago
Read the ranking formula out of scepticism and reproduced the ordering in a spreadsheet. It does what it says.
comment on help me understand sarcopenia, I have read the wiki twice in c/glp1muscle · 1 points · 4 months ago
Have the lifts held, dropped, or moved around?
comment on [Question] Canada — has anyone got a straight answer on special authorization in c/glp1canada · 8 points · 4 months ago
Yes. Approval and coverage are separate, and this board conflates them in about half its threads.
comment on Canada: API source, and what it actually costs here in c/compounding · 2 points · 4 months ago
the shortage list is the whole legal hinge and people skip it
comment on how much of what we believe about endpoint actually comes from TRIUMPH threads in c/trialwatch · 152 points · 4 months ago
Agreed.
hub_ops is right about the programme names. They are different populations with different endpoints.
comment on [Question] how do you actually verify MASH in c/survodutide · 99 points · 4 months ago
Spent an evening on the histology scoring system and understood the trial literature far better afterwards.